Porcine Vaccines Market (Disease Indication - Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD); End use - Veterinary Hospitals and Hog Production Farms; Technology - Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2030

Porcine Vaccines Market - Snapshot

The global porcine vaccines market is expanding due to growing prevalence of swine diseases across the globe. The global porcine vaccines market was valued at US$ 1,784.0 Mn in 2016 and is projected to expand at a compounded annual growth rate (CAGR) of over 7.0% from 2017 to 2025, to reach value of US$ 3,208.8 Mn by 2025. The global market is witnessing growth at a relatively high rate, owing to rise in investments by governments in the field of animal health care, high incidence of swine fever, increase in R&D expenses incurred for eradicating porcine health issues, and surge in the demand for porcine meat and gelatin.

Porcine vaccine is an administrative as well as clinical drug that helps in improving health of swine and protects them from deadly viruses, bacteria, and pathogens. Diseases such as diarrhea, swine influenza, porcine reproductive and respiratory syndrome, and porcine circovirus associated disease (PCVAD) have been greatly reduced from spreading in an endemic manner. A few diseases such as foot & mouth disease and cholera high fever have been eliminated in swine in North America and Europe through vaccination. The success of animal vaccination remains as an ideal interval for booster vaccination.

A porcine vaccine aids the swine or hogs suffering from epidemic porcine diseases. It also improves overall efficiency in protecting pigs from deadly viruses and increases the production level of high-quality meat for consumption. High prevalence and incidence rates of porcine epidemic diarrhea (PED), swine flu, and porcine reproductive and respiratory syndrome (PRRS) in swine production farms worldwide have resulted in increase in early vaccination of piglets and adult pigs. There has been increase in the number of awareness programs about porcine diseases and rise in the number of joint venture programs by key players in different regions for research and development of swine vaccines. These factors are collectively projected to drive the demand for porcine vaccines across the world in the near future. Also, technological advancements such as combined vaccine production and DNA vaccines enable agriculture farmers to produce disease-free pigs. This factor is estimated to fuel the porcine vaccines market in the near future.

The global porcine vaccines market has been broadly segmented based on technology, disease indication, end-user, and region. In terms of technology, the global market has been categorized into inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. The inactivated vaccines segment accounted for a key share (in terms of revenue) of the global market in 2016. The live attenuated vaccines segment is estimated to expand at a significant growth rate during the forecast period and is estimated to gain a significant market share by 2025. DNA vaccines also offer several advantages over live attenuated vaccines and inactivated vaccines and thus, DNA vaccines are increasingly gaining popularity among veterinary hospitals and hog production farms.

In terms of disease indication, the global porcine vaccines market has been divided into diarrhea, swine influenza, arthritis, Bordetella rhinitis, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus associated disease (PCVAD), and others (CHRS, leptospirosis, etc.). Diarrhea and swine influenza segments dominated the global market in 2016 and are likely to continue their dominance from 2017 to 2025, with a marginal increase in their market shares by 2025. Increasing production of pigs in farms for meat, gelatin, and other products; changes in climate including global warming; overfeeding of protein diet; and increasing occurrence of genetically modified strains of influenza viruses have led to significant shares held by diarrhea and swine influenza segments in the global market. In terms of end-user, the global market has been divided into veterinary hospitals and hog production farms. The hog production farms segment is estimated to gain a significant market share by 2025, due to increasing demand for production of pigs for meat and other products.

Geographically, the global porcine vaccines market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2016 and is projected to lose market share by 2025. The market in North America is primarily driven by rapid increase in pig cultivation and rise in infection of pigs caused by viruses such as PEDV, PCV, and PRRSV in the U.S. Moreover, rise in contract farming and independent farming for pig production has been observed in the U.S., which is projected to fuel the hog production farms segment of the market in the U.S. during the forecast period. Asia Pacific is projected to be a rapidly expanding market for porcine vaccines during the forecast period. China dominates the porcine vaccines market in Asia Pacific. The market in  Rest of Asia Pacific (including Vietnam, the Philippines, etc.) is estimated to expand at a significant CAGR during the forecast period.

Companies such as Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., and Zoetis, Inc. were major players in the global porcine vaccines market in 2016. Zoetis, Inc. dominated the market with its diversified product portfolio, extensive geographical presence, and acquisition strategies. In 2015, the company invested over US$ 1.0 Bn in two largest acquisitions. One of them was the acquisition of PHARMAQ, which strengthened Zoetis’ core livestock business division. Other players operating in the global market include Bimeda Animal Health, Vetoquinol, and Bayer AG. Companies are adopting the strategy of acquisitions and collaborations to enhance and strengthen their geographical presence.

Growing Awareness about Improving the Health of Pigs to Bring Tremendous Growth Opportunities for the Porcine Vaccine Market

The prevalence of diseases and disorders among animals caused due to various types of viruses and bacteria has led to a massive number of fatalities. The growing influence of these diseases due to the viruses and bacteria and the rising awareness among a large chunk of the populace in terms of vaccinating the animals to protect them will serve as a prominent growth factor for the porcine vaccine market during the forecast period of 2016-2024.

Diseases ranging from diarrhea to swine influenza affect a large number of pigs across the globe. Many viruses and bacteria also infect animals, especially domesticated animals on a large scale. The Porcine Circovirus (PCV) is one such virus that affects the health of pigs extensively. It is a tiny, single-stranded, non-enveloped DNA virus that replicates on its own in eukaryotic cells. This virus can be dangerous, sometimes fatal for pigs. Thus, to decrease the infection levels, many individuals are focusing on regularly vaccinating the animals, thus increasing the growth rate of the porcine vaccine market.

The multiplying rate of pork consumption and the rising demand for animal-based food products will help in boosting the growth prospects of the porcine vaccine market. Manufacturers in the porcine vaccine market are finding ways to make the vaccine more affordable so that the revenues can be increased exponentially. The ongoing research and development activities are enabling the players in the porcine vaccine market to discover novel insights which eventually increase the growth prospects.

The growing utilization of pigs for numerous purposes including gelatin, meat, and other products is increasing the demand for pig breeding, which will increase the growth rate of the porcine vaccine market substantially.

The COVID-19 pandemic has a little negative effect on the porcine vaccine market as the healthcare and veterinary sector was exempted from the strict lockdown restrictions imposed at the start of the pandemic across numerous countries. Some disruptions were observed regarding supply chain and logistics, which has a minimal negative impact on the growth.  

The global porcine vaccines market has been segmented as below:

by Disease

• Diarrhea
• Swine Influenza
• Arthritis
• Bordetella Rhinitis
• Porcine Reproductive and Respiratory Syndrome (PRRS)
• Porcine Circovirus Associated Disease (PCVAD)
• Others (CHRS, Leptospirosis, etc.)

by Technology

• Inactivated Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Conjugate Vaccines
• DNA Vaccines

by End-user

• Veterinary Hospitals
• Hog Production Farms

by Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• South Africa
• Rest of Middle East & Africa

Chapter 1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2.Assumptions and Research Methodology

Chapter 3.Executive Summary : Global Porcine Vaccines Market

Chapter 4.Market Overview
4.1. Introduction
       4.1.1. Definition
       4.1.2. Market Evolution / Developments
4.2.  Overview
4.3. Market Dynamics
       4.3.1. Drivers
       4.3.2. Restraints
       4.3.3. Opportunities
4.4. Global Porcine Vaccines Market Analysis and Forecast, 2015–2025
       4.4.1. Market Revenue Projection (US$ Mn)
4.5. Porter’s Five Forces Analysis
4.6. Market Outlook
4.7.Regulatory Scenario Assessment
       4.7.1. North America
       4.7.2. Europe
       4.7.3. Asia Pacific
4.8.Disease Indication Comparison, by Region
       4.8.1. North America
       4.8.2. Europe 
       4.8.3. Asia Pacific
       4.8.4. Latin America
       4.8.5. Middle East & Africa
4.9.Swine Production Level, by Region/State
       4.9.1. North America
       4.9.2. Europe 
       4.9.3. Asia Pacific
       4.9.4. Latin America
4.10.Product Launches and Innovations
4.11. Recent Market Activities
4.12.Introduction of New Types of Vaccines
4.13. Snapshot of Market Trends and Issues

Chapter 5.Global Porcine Vaccines Market Analysis and Forecast, by End-user   
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast by End-user, 2015–2025
       5.3.1. Inactivated Vaccines
       5.3.2. Live Attenuated Vaccines
       5.3.3. Toxoid Vaccines
       5.3.4. Recombinant Vaccines
       5.3.5. Conjugate Vaccines
       5.3.6. DNA Vaccines
5.4. Market Attractiveness, by End-user   

Chapter 6.Global Porcine Vaccines Market Analysis and Forecast, by Disease Indication 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Disease Indication, 2015–2025
       6.3.1. Diarrhea 
       6.3.2. Swine Influenza 
       6.3.3. Arthritis
       6.3.4. Bordetella Rhinitis 
       6.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS) 
       6.3.6. Porcine Circovirus Associated Disease (PCVAD)
       6.3.7. Others
6.4. Market Attractiveness, by Disease Indication 

Chapter 7.Global Porcine Vaccines Market Analysis and Forecast, by End-user   
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2015–2025
       7.3.1. Veterinary Hospitals
       7.3.2. Hog Production Farms
7.4. Market Attractiveness, by End-user   

Chapter 8.Global Porcine Vaccines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
       8.2.1. North America 
       8.2.2. Europe 
       8.2.3. Asia Pacific 
       8.2.4. Latin America 
       8.2.5. Middle East & Africa 
8.3. Market Attractiveness, by Country/Region 

Chapter 9.North America Porcine Vaccines Market Analysis and Forecast
9.1. Introduction
       9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2015–2025
       9.2.1. Inactivated Vaccines
       9.2.2. Live Attenuated Vaccines
       9.2.3. Toxoid Vaccines
       9.2.4. Recombinant Vaccines
       9.2.5. Conjugate Vaccines
       9.2.6. DNA Vaccines
9.3. Market Value Forecast, by Disease Indication, 2015–2025
       9.3.1. Diarrhea 
       9.3.2. Swine Influenza 
       9.3.3. Arthritis
       9.3.4. Bordetella Rhinitis 
       9.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS) 
       9.3.6. Porcine Circovirus Associated Disease (PCVAD)
       9.3.7. Others
9.4. Market Value Forecast, by End-user, 2015–2025
       9.4.1. Veterinary Hospitals
       9.4.2. Hog Production Farms
9.5. Market Value Forecast, by Country, 2015–2025
       9.5.1. U.S.
       9.5.2. Canada
9.6. Market Attractiveness Analysis 
       9.6.1. By End-user   
       9.6.2. By Disease Indication 
       9.6.3. By End-user   
       9.6.4. By Country

Chapter 10.Europe Porcine Vaccines Market Analysis and Forecast
10.1.Introduction
       10.1.1. Key Findings
10.2.Market Value Forecast, by End-user, 2015–2025
       10.2.1. Inactivated Vaccines
       10.2.2. Live Attenuated Vaccines
       10.2.3. Toxoid Vaccines
       10.2.4. Recombinant Vaccines
       10.2.5. Conjugate Vaccines
       10.2.6. DNA Vaccines
10.3.Market Value Forecast, by Disease Indication, 2015–2025
       10.3.1. Diarrhea 
       10.3.2. Swine Influenza 
       10.3.3. Arthritis
       10.3.4. Bordetella Rhinitis 
       10.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS) 
       10.3.6. Porcine Circovirus Associated Disease (PCVAD)
       10.3.7. Others
10.4.Market Value Forecast, by End-user, 2015–2025
       10.4.1. Veterinary Hospitals
       10.4.2. Hog Production Farms
10.5.Market Value Forecast, by Country/Sub-region, 2015–2025
       10.5.1. Germany
       10.5.2. U.K.
       10.5.3. France
       10.5.4. Spain
       10.5.5. Italy
       10.5.6. Russia
       10.5.7. Rest of Europe
10.6.Market Attractiveness Analysis 
       10.6.1. By End-user   
       10.6.2. By Disease Indication 
       10.6.3. By End-user   
       10.6.4. By Country/Sub-region

Chapter 11.Asia Pacific Porcine Vaccines Market Analysis and Forecast
11.1.Introduction
       11.1.1. Key Findings
11.2.Market Value Forecast, by End-user, 2015–2025
       11.2.1. Inactivated Vaccines
       11.2.2. Live Attenuated Vaccines
       11.2.3. Toxoid Vaccines
       11.2.4. Recombinant Vaccines
       11.2.5. Conjugate Vaccines
       11.2.6. DNA Vaccines
11.3.Market Value Forecast, by Disease Indication, 2015–2025
       11.3.1. Diarrhea 
       11.3.2. Swine Influenza 
       11.3.3. Arthritis
       11.3.4. Bordetella Rhinitis 
       11.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS) 
       11.3.6. Porcine Circovirus Associated Disease (PCVAD)
       11.3.7. Others
11.4.Market Value Forecast, by End-user, 2015–2025
       11.4.1. Veterinary Hospitals
       11.4.2. Hog Production Farms
11.5.Market Value Forecast, by Country/Sub-region, 2015–2025
       11.5.1. China
       11.5.2. Japan
       11.5.3. India
       11.5.4. Australia & New Zealand
       11.5.5. Rest of Asia Pacific
11.6.Market Attractiveness Analysis 
       11.6.1. By End-user   
       11.6.2. By Disease Indication
       11.6.3. By End-user   
       11.6.4. By Country/Sub-region

Chapter 12.Latin America Porcine Vaccines Market Analysis and Forecast
12.1.Introduction
       12.1.1. Key Findings
12.2.Market Value Forecast, by End-user, 2015–2025
       12.2.1. Inactivated Vaccines
       12.2.2. Live Attenuated Vaccines
       12.2.3. Toxoid Vaccines
       12.2.4. Recombinant Vaccines
       12.2.5. Conjugate Vaccines
       12.2.6. DNA Vaccines
12.3.Market Value Forecast, by Disease Indication, 2015–2025
       12.3.1. Diarrhea 
       12.3.2. Swine Influenza 
       12.3.3. Arthritis
       12.3.4. Bordetella Rhinitis 
       12.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS) 
       12.3.6. Porcine Circovirus Associated Disease (PCVAD)
       12.3.7. Others
12.4.Market Value Forecast, by End-user, 2015–2025
       12.4.1. Veterinary Hospitals
       12.4.2. Hog Production Farms
12.5.Market Value Forecast, by Country/Sub-region, 2015–2025
       12.5.1. Brazil
       12.5.2. Mexico
       12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis 
       12.6.1. By End-user   
       12.6.2. By Disease Indication 
       12.6.3. By End-user   
       12.6.4. By Country/Sub-region

Chapter 13.Middle East & Africa Porcine Vaccines Market Analysis and Forecast
13.1.Introduction
       13.1.1. Key Findings
13.2.Market Value Forecast, by End-user, 2015–2025
       13.2.1. Inactivated Vaccines
       13.2.2. Live Attenuated Vaccines
       13.2.3. Toxoid Vaccines
       13.2.4. Recombinant Vaccines
       13.2.5. Conjugate Vaccines
       13.2.6. DNA Vaccines
13.3.Market Value Forecast, by Disease Indication, 2015–2025
       13.3.1. Diarrhea 
       13.3.2. Swine Influenza 
       13.3.3. Arthritis
       13.3.4. Bordetella Rhinitis 
       13.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS) 
       13.3.6. Porcine Circovirus Associated Disease (PCVAD)
       13.3.7. Others
13.4.Market Value Forecast, by End-user, 2015–2025
       13.4.1. Veterinary Hospitals
       13.4.2. Hog Production Farms
13.5.Market Value Forecast, by Country/Sub-region, 2015–2025
       13.5.1. South Africa
       13.5.2. Rest of Middle East & Africa
13.6.Market Attractiveness Analysis 
       13.6.1. By End-user   
       13.6.2. By Disease Indication 
       13.6.3. By End-user   
       13.6.4. By Country/Sub-region

Chapter 14.Competition Landscape
14.1.Market Player – Competition Matrix (by Tier and Size of companies)
14.2.Market Share Analysis, by Company (2016)
       14.2.1. Bayer AG
                14.2.1.1. Overview
                14.2.1.2. Financials
                14.2.1.3. Recent Developments
                14.2.1.4. Strategy
       14.2.2. Bimeda Animal Health 
                14.2.2.1. Overview
                14.2.2.2. Financials
                14.2.2.3. Recent Developments
                14.2.2.4. Strategy
       14.2.2. Boehringer Ingelheim GmbH 
                14.2.3.1. Overview
                14.2.3.2. Financials
                14.2.3.3. Recent Developments
                14.2.3.4. Strategy
       14.2.4. Ceva Santé Animale
                14.2.4.1. Overview
                14.2.4.2. Financials
                14.2.4.3. Recent Developments
                14.2.4.4. Strategy 
       14.2.5. Elanco (Eli Lilly and Company)
                14.2.5.1. Overview
                14.2.5.2. Financials
                14.2.5.3. Recent Developments
                14.2.5.4. Strategy
       14.2.6. Merck & Co., Inc.
                14.2.6.1. Overview
                14.2.6.2. Financials
                14.2.6.3. Recent Developments
                14.2.6.4. Strategy 
       14.2.7. Vetoquinol
                14.2.7.1. Overview
                14.2.7.2. Financials
                14.2.7.3. Recent Developments
                14.2.7.4. Strategy
       14.2.8. Zoetis, Inc.
                14.2.8.1. Overview
                14.2.8.2. Financials
                14.2.8.3. Recent Developments
                14.2.8.4. Strategy
       14.2.9. Others